Persistence of chemosensory deficiencies in patients of COVID-19: our experience
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20213219Keywords:
COVID-19, Anosmia, DysguesiaAbstract
Background: Severe acute respiratory syndrome coronavirus-2 (SARS COV-2) infection has caused a global pandemic that has spread like wildfire throughout the world over a very short period of time. Though it may present with a multitude of symptoms mainly respiratory; neurological symptoms like smell and taste disturbances have emerged with greater frequency and sometimes as the only presentation in mild and moderate cases.
Methods: This study was conducted at a tertiary hospital dedicated to COVID care in Northern India. Approval was sought from the Institutional Ethics Committee before the commencement of the study. Appropriate written and informed consent was obtained from all patients before their induction. All confirmed COVID -19 patients, previously documented to have chemosensory deficits of anosmia and dysgeusia over 3 months were followed up by over a period of 8 weeks. Data was collected on the basis of a comprehensive questionnaire telephonically at intervals of 2 weeks and 8 weeks and recorded.
Results: During the period of study, from a sample of 450 patients, a total of 199 patients complained of chemosensory dysfunction out of which 63.8% were males (Figure 1). A total of 145 patients had dysgeusia and 136 had anosmia with a male preponderance of 62% and 63.9% respectively.
Conclusions: Residual post-COVID symptoms last and whether they may permanently affect quality of life further studies are required.
References
Altundag A, Saatci O, Sanli DET. The temporal course of COVID-19 anosmia and relation to other clinical symptoms. Eur Arch Otorhinolaryngol. 2020.
Gori A, Leone F, Loffredo L. COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. Front Neurol. 2020;11:956.
Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(4):481-3.
Pang KW, Chee J, Subramaniam S. Frequency and Clinical Utility of Olfactory Dysfunction in COVID-19: a Systematic Review and Meta-analysis. Curr Allergy Asthma Rep. 2020;20:76.
European Rhinologic Society (ERS). COVID-19: What’s NOW? ERS members email. https://mailchi.mp/4c241a511c2d/important-info-on-covid-19?e=d610a2d247. Accessed on 4th November, 2020.
Kaye R, Chang CWD, Kazahaya K, Brereton J, Denneny JC. COVID-19 Anosmia Reporting Tool: Initial Findings. Otolaryngology–Head and Neck Surgery. 2020;163(1):132-4.
Heidari F, Karimi E, Firouzifar M. Anosmia as a prominent symptom of COVID-19 infection. Rhinol. 2020;58:302-3.
Tsivgoulis G, Fragkou PC, Lachanis S. Olfactory bulb and mucosa abnormalities in persistent COVID-19 induced anosmia: a magnetic resonance imaging study. Eur J Neurol. 2020.
Klein H, Asseo KN. Onset, duration, and persistence of taste and smell changes and other COVID-19 symptoms: longitudinal study in Israeli patients. medrXiv. 2020.
Kandemirli SG, Altundag A, Yildirim D, TekcanSanli DE, Saatci O. Olfactory Bulb MRI and paranasal sinus CT findings in persistent COVID-19 anosmia. AcadRadiol. 2020;1:1076-6332.
Hopkins C, Surda P, Whitehead E. Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study. J of Otolaryngol - Head & Neck Surg. 2020;49:26.
Bonenberger A. Anosmia: COVID-19's mysterious side effect. Yale Medicine. https://medicine.yale. edu/news/yale-medicine-magazine/anosmia-covid19s-mysterious-side-effect/. Accessed on 5th November, 2020.
